Biperiden
Based on 1 Customer Validation
Biperiden (KL 373) is a non-selective muscarinic receptor antagonist that competitively binds to M1 muscarinic receptors, thereby inhibiting acetylcholine and enhancing dopamine signaling in the central nervous system. Biperiden has the potential for the research of Parkinson's disease and other related psychiatric disorders.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.11%
- CAS No.: 514-65-8
- Formule: C21H29NO
- Masse moléculaire:311.46
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
Neurotransmitter Receptor Compound Library
HY-L062
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Activité biologique
Biperiden (29.6 μg/ml, 72 hours) can significantly induce apoptosis and inhibit proliferation at high doses in human pancreatic ductal adenocarcinoma cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Panc-1, Panc-2 and BxPC3 human pancreatic ductal adenocarcinoma cells
-
Concentration:29.6 μg/mL
-
Incubation Time:72 hours
-
Result:Inhibited cell proliferation at 72 hours significantly by reducing nuclear c-Rel translocation.
Biperiden (intraperitoneal injection, 8 mg/kg, every 8 hours, 10 days) can reduce frequency of spontaneous seizures and extracellular hippocampal glutamate levels while cause a long-term decrease in hippocampal excitability[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Subcutaneous xenograft mouse using Panc-1 human pancreatic ductal adenocarcinoma cells[1]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; everyday; 3 weeks
-
Result:Tumor size reduced by 83%.
-
Animal Model:Male Wistar rats (200-250 g)[2]
-
Dosage:8 mg/kg
-
Administration:Intraperitoneal injection; every 8 hours; 10 days
-
Result:Reduced late seizures by about three times with no affecting emotional memory damage.
Chemical Information
-
CAS No. 514-65-8
-
Appearance Solid
-
Masse moléculaire 311.46
-
Formule C21H29NO
-
Color White to off-white
-
SMILES
OC([C@H]1C[C@@H]2C=C[C@H]1C2)(CCN3CCCCC3)C4=CC=CC=C4
-
Synonyms
KL 373
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvant et solubilité
DMSO : 50 mg/mL (160.53 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 1.82 mg/mL (5.84 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Leonie Konczalla，et al. Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. Int J Cancer. 2020 Mar 15;146(6):1618-1630. [Content Brief]
[2]. Simone Bittencourt, et al. Modification of the natural progression of epileptogenesis by means of biperiden in the pilocarpine model of epilepsy. Epilepsy Res. 2017 Dec;138:88-97. doi: 10.1016/j.eplepsyres.2017.10.019. Epub 2017 Oct 29. [Content Brief]
[3]. Pehl C, et al. Effects of two anticholinergic drugs, trospium chloride and biperiden, on motility and evoked potentials of the oesophagus. Aliment Pharmacol Ther. 1998 Oct;12(10) [Content Brief]
[4]. Kornhuber J, et al. Identification of novel functional inhibitors of acid sphingomyelinase. PLoS One. 2011;6(8) [Content Brief]
[5]. Myhrer T, et al. Antiparkinson drugs used as prophylactics for nerve agents: studies of cognitive side effects in rats. Pharmacol Biochem Behav. 2008 Jun;89(4):633-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 3.2107 mL | 16.0534 mL | 32.1069 mL | 80.2671 mL |
| 5 mM | 0.6421 mL | 3.2107 mL | 6.4214 mL | 16.0534 mL | |
| DMSO | 10 mM | 0.3211 mL | 1.6053 mL | 3.2107 mL | 8.0267 mL |
| 15 mM | 0.2140 mL | 1.0702 mL | 2.1405 mL | 5.3511 mL | |
| 20 mM | 0.1605 mL | 0.8027 mL | 1.6053 mL | 4.0134 mL | |
| 25 mM | 0.1284 mL | 0.6421 mL | 1.2843 mL | 3.2107 mL | |
| 30 mM | 0.1070 mL | 0.5351 mL | 1.0702 mL | 2.6756 mL | |
| 40 mM | 0.0803 mL | 0.4013 mL | 0.8027 mL | 2.0067 mL | |
| 50 mM | 0.0642 mL | 0.3211 mL | 0.6421 mL | 1.6053 mL | |
| 60 mM | 0.0535 mL | 0.2676 mL | 0.5351 mL | 1.3378 mL | |
| 80 mM | 0.0401 mL | 0.2007 mL | 0.4013 mL | 1.0033 mL | |
| 100 mM | 0.0321 mL | 0.1605 mL | 0.3211 mL | 0.8027 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Biperiden Related Classifications
HY-13204A Related Classifications
Powered by Bioz